Skip to Main Content

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of Aprepitant Injectable Emulsion in Early Hospitalized Adult Patients with COVID-19

Conditions

COVID-19 Inpatient | COVID-19 Outpatient

Phase COVID-II

What is the purpose of this trial?

The purpose of this research study is to see if a medicine called CINVANTI can be used safely and effectively to treat adults hospitalized because of COVID-19. Aprepitant may help in the treatment of COVID-19 because aprepitant may reduce the inflammation caused by the virus and may also reduce the ability of the virus to divide and increase in numbers. Aprepitant may also reduce the cough associated with COVID-19. All participants will receive daily treatment of study drug for up to 14 days and will be followed weekly for 8 weeks.

  • Trial with
    Heron Therapeutics, Inc.
  • Start Date
    09/10/2020
  • End Date
    02/28/2021

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    07/15/2021
  • Study HIC
    #2000028569